Compugen (CGEN) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Normal Saline, Com701 | Ovarian Cancer, Ovarian Cancer Recurrent | phase1AndPhase2 | Recruiting | A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer | Mar 12, 2025 | ― |
| Dose Escalation: Com902 Monotherapy., Evaluation Of Safety/Tolerability: Com902 In Combination With Com701 (Both At The Rdfe), Cohort Expansion: Com902 (Rdfe) Monotherapy., Cohort Expansion: Com902 In Combination With Com701 (Both At The Rdfe)., Cohort Expansion: Triplet Combination Of Com902 + Com701 + Pembrolizumab. | Multiple Myeloma, Ovarian Cancer, Lung Cancer, Advanced Cancer, Hnscc, Colon Cancer, Plasma Cell Neoplasm, Microsatellite Stable Colorectal Carcinoma, Mss-Crc | Phase I | Active Not Recruiting | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | Apr 15, 2020 | ― |
| Com701, Com701 With Opdivo (Nivolumab). | Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer, Lung Cancer, Advanced Cancer, Neoplasm Malignant, Endometrial Cancer, Colo-Rectal Cancer, Ovarian Neoplasm, Lung Neoplasm | Phase I | Completed | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | Sep 10, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Normal Saline, Com701 | phase1AndPhase2 | Ovarian Cancer, Ovarian Cancer Recurrent | Recruiting | A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer | Mar 12, 2025 | ― |
| Dose Escalation: Com902 Monotherapy., Evaluation Of Safety/Tolerability: Com902 In Combination With Com701 (Both At The Rdfe), Cohort Expansion: Com902 (Rdfe) Monotherapy., Cohort Expansion: Com902 In Combination With Com701 (Both At The Rdfe)., Cohort Expansion: Triplet Combination Of Com902 + Com701 + Pembrolizumab. | Phase I | Multiple Myeloma, Ovarian Cancer, Lung Cancer, Advanced Cancer, Hnscc, Colon Cancer, Plasma Cell Neoplasm, Microsatellite Stable Colorectal Carcinoma, Mss-Crc | Active Not Recruiting | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | Apr 15, 2020 | ― |
| Com701, Com701 With Opdivo (Nivolumab). | Phase I | Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer, Lung Cancer, Advanced Cancer, Neoplasm Malignant, Endometrial Cancer, Colo-Rectal Cancer, Ovarian Neoplasm, Lung Neoplasm | Completed | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | Sep 10, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Compugen (IL:CGEN) have in its pipeline
Compugen IL:CGEN is currently developing the following drugs: Normal Saline, Com701, Dose Escalation: Com902 Monotherapy., Evaluation Of Safety/Tolerability: Com902 In Combination With Com701 (Both At The Rdfe), Cohort Expansion: Com902 (Rdfe) Monotherapy., Cohort Expansion: Com902 In Combination With Com701 (Both At The Rdfe)., Cohort Expansion: Triplet Combination Of Com902 + Com701 + Pembrolizumab., Com701, Com701 With Opdivo (Nivolumab).. These drug candidates are in various stages of clinical development as the company works toward FDA approval.